Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ibritumomab

Zevalin (Ibritumomab Tiuxetan murine monoclonal antibody, produced in a CHO cell line, targeted against the CD20 antigen) IDEC Pharmaceuticals Non-Hodgkin s lymphoma... [Pg.381]

Ibritumomab tiuxetan (Zevalin) MoAB radiolabeled Relapsed refractory follicular NHL Phase II response... [Pg.447]

ZevaHn Ibritumomab tiuxetan Biogen Idee Radiolabeled anti-CD20 Non-Hodgkin s lymphoma 2002... [Pg.580]

Ibritumomab tiuxetan Zevalin Murine IgGltc anti-CD20, radiolabeled Y-90 Relapsed or refractory low-grade, follicular transformed non-Hodgkin s lymphoma 2002 United States... [Pg.114]

Immunomodulators affect the functioning of the immune system. Immune functions may be promoted as well as suppressed by these agents. In this section interferon alpha, BCG, immunocyanin and aldesleukine and the monoclonal antibodies, alem-tuzumab, bevacizumab, cetuximab, trastuzumab, rit-uximab and ibritumomab tiuxetan will be briefly discussed. [Pg.460]

Dosage form Zevalin kits provide for the radiolabeling of ibritumomab tiuxetan with In-111 and with Y-90. Each of the kits... [Pg.309]

Clinical pharmacology Ibritumomab tiuxetan binds specifically to the CD20 antigen with an apparent affinity (Ka) of 14 to 18 nM. The antigen is expressed on pre-B- and mature B-lymphocytes and on greater than 90% of B-cell non-Hodgkin s... [Pg.310]

Ibritumomab tiuxetan, monoclonal antibody directed against the CD20 antigen, produced in CHO cells... [Pg.448]

Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-FIodgkin s lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Flodgkin s lymphoma. The therapeutic regimen includes Rituximab, Indium-111 Ibritumomab Tiuxetan, and Yttrium-90 Ibritumomab Tiuxetan... [Pg.471]

Zevalin has been approved by the U S. FDA for radioimmunotherapy in B-cell lymphoma (39). The activity of ibritumomab tiuxetan had been evaluated or is under investigation for rituximab-refractory lymphoma patients, relapsed diffuse large B-cell or mantle cell lymphoma patients, or as a part of high-dose chemotherapy with autologous hematopoietic stem cell support (40). The results of phase I, 11, and randomized trials showed that the single doses of Zevalin are safe and effective in the treatment of patients with relapsed B-cell NHL with a response rate of 60%-80% (40). Unfortunately, no data are available regarding the impact of polymorphisms on the clinical outcomes after Zevalin therapy. [Pg.211]

Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan... [Pg.227]

Witzig TE. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin s lymphoma. Semin Oncol 2003 30 11-16. [Pg.227]

Weigert O, Illidge T, Hiddemann W et al. Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006 107 686-695. [Pg.227]

Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin s lymphoma. Cancer Biother Radiopharm 2005 20 185-188. [Pg.227]

Tositumomab is another anti-CD20 monoclonal antibody and is complexed with iodine 131 (131I). Tositumomab is used in two-step therapy in patients with CD20-positive, follicular non-Hodgkin s lymphoma whose disease is refractory to rituximab and standard chemotherapy. Toxicities are similar to those for ibritumomab and include severe cytopenias such as thrombocytopenia and neutropenia. Tositumomab should not be administered to patients with greater than 25% bone marrow involvement. [Pg.1198]

Parenteral 5 mg powder, reconstitute for injection Ibritumomab tiuxetan (Zevalin)... [Pg.1206]

Shimoni A, Zwas ST, Oksman Y, Hardan I, et al. 2007. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin s lymphoma. Exp Hematol. 35 534-540. [Pg.126]

See other pages where Ibritumomab is mentioned: [Pg.603]    [Pg.604]    [Pg.590]    [Pg.1380]    [Pg.605]    [Pg.723]    [Pg.607]    [Pg.62]    [Pg.461]    [Pg.309]    [Pg.309]    [Pg.310]    [Pg.310]    [Pg.555]    [Pg.204]    [Pg.211]    [Pg.211]    [Pg.332]    [Pg.119]    [Pg.119]    [Pg.119]   
See also in sourсe #XX -- [ Pg.119 ]

See also in sourсe #XX -- [ Pg.98 ]

See also in sourсe #XX -- [ Pg.98 ]

See also in sourсe #XX -- [ Pg.141 ]



SEARCH



90Y-ibritumomab tiuxetan

Cancer treatments ibritumomab

Ibritumomab tiuxetan

Ibritumomab tiuxetan (Zevalin IDEC

Monoclonal antibody therapy Ibritumomab Tiuxetan

© 2024 chempedia.info